<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319461</url>
  </required_header>
  <id_info>
    <org_study_id>UH-HYA-01-04</org_study_id>
    <nct_id>NCT01319461</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee</brief_title>
  <official_title>Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee: a Randomized, Masked Observed, Double Blind, Placebo Controlled, Multicenter Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Med Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fidia Farmaceutici s.p.a.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Med Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Hyalgan, at a dose of 20mg/2ml administered as 5
      intraarticular injections at weekly intervals, for the sustained relief of pain and
      amelioration of joint dysfunction in patients of OA of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>sterile normal saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyalgan injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyalgan</intervention_name>
    <description>Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.</description>
    <arm_group_label>Hyalgan injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sterile normal saline</intervention_name>
    <description>Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.</description>
    <arm_group_label>sterile normal saline injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Male or female patients whose specific ages are &gt; 50 years old, in general health.
             2.Must be ambulatory (assistive devices allowed) 3.Patient was diagnosed as OA of knee
             joint by American College of Rheumatology (ACR) criteria ; [ ie,knee pain, and any one
             of the following:age&gt;50 years,crepitus, or morning stiffness&lt;30 minutes in duration ]
             4.Radiographic confirmation of OA with Kellgren-Lawrence Ⅱ-Ⅲ score (mild to
             moderate)at the target joint (anterior-posterior views) with predominance in the
             tibia-femoral compartment 5.VAS score ≧40 mm for 50 foot of walking pain.

        Exclusion Criteria:

          -  1.Patients with severe degeneration of knee joint with marked joint narrowing, marked
             varus or valgus deformity of the knee greater than 12 o. 2.Patients with hepatic or
             renal failure, or other chronic severe diseases that can interfere with the outcome.
             3.A known history of psychiatric diseases, significant neurological diseases, allergy
             or sensitivity to hyaluronic acid or avian protein. 4.Patients receive steroid
             intraarticular injection, anti-inflammatory agents less than two weeks. 5.Patients
             with joint disorders: inflammatory joint disease, specific arthropathy
             (chondrocalcinosis, joint effusion &gt;30ml), severe axis deviations or instabilities,
             joint or skin infections, joint prostheses of the lower limbs, symptomatic hip.
             6.Significant alcohol, drug or medication abuse as judged by the investigator.
             7.Pregnancy determined by clinical evaluation or urine testing for nursing women
             and/or women of childbearing potential not using a medically approved means of
             contraception (i.e., oral contraceptives, intrauterine devices, diaphragm or
             Norplant). 8.Patients who have taken any other &quot;investigational&quot; drug within one month
             prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Ching Tsai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National taiwan university hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eric Chang</name_title>
    <organization>Med Pharma Co., Ltd.</organization>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Hyalgan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

